Imaging & Structural Heart · Practice-Changing Data

Rethinking a Sacred Cow: Sublingual Nitroglycerin Before Pre-TAVI CT Angiography

New prospective data presented at SCCT 2026 suggest a long-standing contraindication may be doing more harm than good in appropriately selected patients.

Cardiology & Cardiovascular Investing Digest · Practice Update

Coronary artery disease coexists with severe aortic stenosis in roughly six or seven of every ten patients referred for valve replacement.

Because of that overlap, Society for Cardiovascular Computed Tomography (SCCT) guidance calls for routine coronary assessment as part of pre-procedural planning.

Sublingual nitroglycerin has long been the standard trick for sharpening those images, since it dilates the coronary arteries and reduces motion-related blur.

Yet the same guidance has historically flagged nitroglycerin as relatively contraindicated in severe AS, out of concern that its hypotensive effect could be dangerous in a stenotic, preload-dependent ventricle.

That tension has left many imaging labs either skipping the drug in this population or using it off-protocol without strong evidence either way.

A new prospective study presented at the 2026 SCCT annual scientific meeting directly tests that old assumption.

Mean systolic blood pressure fell after sublingual nitroglycerin and then stabilized through discharge, with no associated symptoms in the majority of patients.

What the Study Found

Investigators enrolled 109 patients with severe AS, mean age 79.4 years, referred for coronary CT angiography ahead of TAVI.

Everyone in the cohort received 0.8 mg of sublingual nitroglycerin, after excluding patients with baseline hypotension, severely reduced ejection fraction, critical AS, or other standard contraindications.

Mean systolic blood pressure dropped from 158 mmHg at baseline to 140 mmHg after the scan and remained stable at 136 mmHg through discharge.

Just over a third of patients, 38.5%, had a drop in systolic pressure greater than 20 mmHg, but none of these drops were tied to symptoms.

The most common side effects were mild and self-limited: headache in 8.2% and dizziness in 7.3%.

Against a propensity-matched control group that did not receive the drug, the nitroglycerin group showed sharply better image quality on nearly every metric the researchers tracked.

Imaging Performance, Head-to-Head

Metric	Nitroglycerin Group	Control Group	P value
Contrast-to-noise ratio	30.4	18.5	<0.001
Signal-to-noise ratio	25.5	15.1	<0.001
Coronary blood volume index	3.1	2.0	<0.001
False-positive scans	8	23	—
Positive predictive value	75.0%	48.9%	0.033
Diagnostic accuracy	84.9%	67.6%	0.036

The nitroglycerin group also had significantly fewer scans classified as the ambiguous CAD-RADS 3 category, meaning fewer equivocal reads that would typically trigger a follow-up invasive study.

Consistent with that, the study group trended toward needing fewer subsequent invasive coronary angiograms, 35.6% versus 49.3% in controls, a 27% relative risk reduction that did not quite reach statistical significance.

Positive predictive value and diagnostic accuracy were both significantly higher in patients who received sublingual nitroglycerin before their scan.

A Practice Change, Not Just a Data Point

The investigators framed their conclusion plainly: sublingual nitroglycerin before CTA in appropriately selected patients with severe AS undergoing TAVI evaluation is safe and well tolerated.

The senior author on the study, who also serves as SCCT's incoming president, told meeting attendees the data have already changed practice at his own center.

The presenting investigator's group now routinely gives sublingual nitroglycerin before pre-TAVR CT in elective, clinically stable patients with severe AS.

Their exclusion criteria mirror the study protocol: baseline systolic blood pressure under 100 mmHg, left ventricular ejection fraction under 30%, critical AS, or any standard contraindication to nitrates.

The clinical logic is straightforward: better coronary visualization means CAD can more often be confidently excluded on CT alone, sparing a same-admission invasive angiogram in a patient already headed for one procedure.

Case in Point

An 81-year-old with symptomatic severe aortic stenosis and a heavily calcified aortic valve is referred for TAVI workup.

Baseline blood pressure is 152/78 mmHg, ejection fraction is 55%, and there is no history of nitrate intolerance.

Following the updated protocol, the CT team gives 0.8 mg of sublingual nitroglycerin five minutes before acquisition.

The resulting scan shows well-opacified, low-noise coronary segments with no significant stenosis, and the heart team proceeds directly to TAVI without a preceding invasive angiogram.

Dosing and Cost

Sublingual nitroglycerin doses in this population have ranged from 0.3 mg to 0.8 mg depending on aortic valve area and institutional protocol.

The drug itself is generic, inexpensive, and widely stocked, which makes this an unusually low-cost intervention with an outsized effect on downstream resource use.

Product	Formulation	Manufacturer	Cash Price (GoodRx)
Nitroglycerin (generic)	0.4 mg sublingual tablet, 25 ct	Multiple generic manufacturers	as low as $9.00
Nitrostat (brand)	0.4 mg sublingual tablet, 25 ct	no ticker (brand marketed by a private generics distributor)	as low as $9.00

Financial disclaimer: stock ratings, price targets, and drug pricing cited in this article are point-in-time snapshots for educational purposes, are not investment advice, and should be independently verified before any clinical or financial decision.

The Investor Lens: Who Benefits from a Streamlined Pre-TAVI Workup

A protocol change that lets more centers safely exclude CAD on CT alone, rather than defaulting to invasive angiography, has ripple effects across the structural heart and cardiac imaging supply chain.

Fewer invasive angiograms per TAVI candidate shifts volume and margin toward CT hardware and toward the valve platforms that depend on efficient, high-throughput screening pipelines.

Company	Ticker	Relevance	Analyst Consensus	12-Mo Price Target
Edwards Lifesciences	NYSE: EW	Leading transcatheter aortic valve (SAPIEN) platform; volume tied to efficient pre-TAVI workup	Buy	$97.58
Medtronic	NYSE: MDT	Competing TAVI platform (Evolut); same CT-dependent screening pathway	Buy	$98.00
GE HealthCare	NASDAQ: GEHC	Major cardiac CT scanner manufacturer; benefits from expanded pre-TAVI CTA volume	Buy	$78.95

Bottom Line

Sublingual nitroglycerin before pre-TAVI coronary CTA, long avoided in severe AS out of caution, appears safe and meaningfully improves image quality in carefully selected, hemodynamically stable patients.

Better images translate directly into fewer equivocal reads, higher diagnostic accuracy, and a real chance to skip an unnecessary invasive angiogram in a patient already facing one procedure.

Cardiologists running structural heart imaging programs should revisit their own institutional protocols and exclusion criteria in light of this evidence.

---

References

1. SCCT 2026: What to Expect in Chula Vista. TCTMD.
2. New CT Guidelines for TAVR Emphasize Standardization, 4-D Acquisition, and Postprocedural Imaging. TCTMD.
3. Nitroglycerin Prices, Coupons and Savings Tips. GoodRx.
4. Edwards Lifesciences (EW) Stock Forecast & Price Targets. StockAnalysis.com.
5. Medtronic (MDT) Stock Forecast & Analyst Price Targets. StockAnalysis.com.
6. GE HealthCare Technologies (GEHC) Stock Forecast & Price Targets. StockAnalysis.com.

Physician education disclaimer: this article summarizes preliminary conference-presented data and is intended for physician education, not as a substitute for institutional protocols, product labeling, or individualized clinical judgment.